ABVD or BEACOPP for advanced Hodgkin lymphoma. Not to BEACOPP. Massimo Federico University of Modena and Reggio Emilia Italy
|
|
- Camron Mills
- 5 years ago
- Views:
Transcription
1 ABVD or BEACOPP for advanced Hodgkin lymphoma Not to BEACOPP Massimo Federico University of Modena and Reggio Emilia Italy
2 What is the best Induction Therapy for Advanced Hodgkin Lymphoma?
3 How to treat patients with advanced Hodgkin Lymphoma (HL)? There is a general agreement that BEACOPPesc is associated with better disease control in terms of response rate, progression free survival and freedom from treatment failure. However, there is no agreement on the superiority of BEACOPPesc over ABVD in terms of Overall Survival (OS).
4 Standard and increased-dose BEACOPP vs COPP-ABVD for advanced HL Freedom from Treatment Failure Overall Survival HD9 trial BEACOPP is superior to COPP/ABVD Diehl V et al, 348(24): , 2003
5 . and outside GHSG???
6 GISL HD2000: ABVD vs CEC vs BEA Federico M et al. 2009
7 Advanced stage: ABVD vs BEACOPP HL disease Stage IIB-IV Stratify: Site; IPS 2 vs 3 Random 1:1 ABVD x 6-8 BEACOPP exc x 4 BEACOPP std x 4 CR, CRU, PR > 80% RT on bulk or residual mass (30 Gy) R< 80%, PD, Relapse High-dose Salvage + RT (20-25 Gy) CR, CRU, PR > 80% RT on bulk or residual mass (30 Gy) R< 80%, PD, Relapse High-dose Salvage + RT (20-25 Gy) Viviani S et al, 2011
8 Viviani S et al, 2011 Freedom from first progression P R O B A B I L I T Y BEACOPP ABVD Pts Events HR p % 85% 70% 69% P R O B A B I L I T Y Event-free survival 80% 78% 72% 69% BEACOPP Pts 155 Events 29 HR 0.69 p 0.12 ABVD Years Years Freedom from second progression P R O B A B I L I T Y BEACOPP ABVD Pts Events HR p % 88% 85% 82% P R O B A B I L I T Y Overall Survival BEACOPP ABVD 90% 89% Pts Events HR p % 86% Years Years
9 EORTC releases final results of advanced Hodgkin Lymphoma study comparing BEACOPP to ABVD (EORTC 20012) At a median follow up of 3.9 years, event free survival, the primary endpoint, was similar between treatment arms. More progressions/ relapses were observed with ABVD than with BEACOPP treatment, while early discontinuations were more frequent with BEACOPP. In this high-risk group, overall survival was not significantly improved with BEACOPP. 2012: P. Carde, as of June 2012
10 Viviani, NEJM 2011 Carde, ASCO 2012 BEACOPP BEACOPP ABVD ABVD BEACOPP ABVD MOPP MOPP ABVD MOPP SINGLE AGENT SINGLE AGENT MOPP SINGLE AGENT BEACOPP SINGLE AGENT
11 Probability Evidence for OS with BEACOPP escalated Regimen 6*BEACOPP esc vs. ABVD 5-year OS difference 10% (95% CI : 13% to 5%) 0.50 ABVD 6*BEACOPP esc Years
12 it is premature to conclude that the magnitude of OS benefit as estimated by the network analysis is real
13
14 HD9 trial: 10 years of follow up Arm A= COPP/ABVD, Arm B= BEACOPP baseline, Arm C= BEACOPP escalated Freedom from Treatment Failure Overall Survival Engert A et al, 27(27): , 2009
15 Borchmann P et al, 2011 A Residual disease after CHT (w/wo initial bulky) B Initial bulky, no residual disease
16 FFTF TTP Engert A et al, 2012 OS
17 ( )
18 Still BEACOPP or no BEACOPP? BEACOPP defenders ABVD defenders
19 BEACOPP or ABVD? Europe BEACOPP defenders USA/UK/Canada ABVD defenders Modified from Massimo Federico
20 Could the treatment of patients with advanced HL according to Risk and Response be the solution?
21 Outcome according to IPS: GISL HD2000 BEA vs ABVD CEC vs ABVD P=.125 P=.676 BEA vs ABVD CEC vs ABVD P=.038 P=.056 Federico M et al, 2009
22 Relative risk of chemoresistance Clin Lymphoma Myeloma Leuk Gobbi PG et al, 2011
23 May 2008 July 2008 Sept 2008
24 HD0607: Overall Survival n = 412 OS at 2Y: 10/412 (97.3%) OS at 3Y: 13/335 (95.8%) TOTAL412 (3) 401 (2) 374 (2) 346 (3 ) 297 (1) 227 (2) 159 (3) 88 (1) 28 (0) 1 (0) By courtesy of A. Gallamini, January 30, 2014
25 * 1 pt died before performing PET2 HD0607: OS by PET2 diagnosis n = 411* OS at 2Y: PET2 NEG: 3/335 (99.0%) PET2 POS: 6/76 (90.4%) OS at 3Y: PET2 NEG: 5/335 (97.8%) PET2 POS: 7/76 (88.2%) MEDIAN FUP PET2 pos 844 days ( q1 483 q3 1088) MEDIAN FUP PET2 neg 972 days ( q1 722 q3 1241) P= PET2 NEG 335 (0) 331 (2) 311 (0) 290 (1) 252 (0) 196 (2) 140 (3) 73 (1) 24 (0) 1 (0) PET2 POS 76 (2) 70 (0) 63 (2) 56 (2) 45 (1) 31 (0) 19 (0) 15 (0) 4 (0) 0 (0) By courtesy of A. Gallamini, January 30, 2014
26 .. As the H2 Study Study Network Study start Initial Therapy Subsequent Therapy H2 Israel ABVD ABVD or BEACOPP according to PET H2 Israel BEACOPPesc BEACOPP or ABVD according to PET IPS T110 TAILORED THERAPY IN HODGKIN LYMPHOMA, BASED ON PREDEFINED RISK FACTORS AND EARLY INTERIM PET/CT, ISRAELI H2 PROTOCOL: PRELIMINARY REPORT ON 317 PATIENTS Dann EJ
27 IPS 0-2 Start with ABVD or ECHELON1
28 IPS 3-7 Start with BEACOPPesc or
29 Thus, taking advantage of all.. RISK B-V RESPONSE
30 Conclusion Data emerging from several randomized controlled trials of a response-oriented approach driven by early PET assessment, and the potential of brentuximab vedotin combinations to improve the efficacy of ABVD with an acceptable toxicity profile, allow us to conclude that the recommendation to give all patients six cycles of BEACOPPesc upfront is not appropriate.
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationHodgkin Lymphoma Status of the art of treatment
11.05.2016 1 Hodgkin Lymphoma Status of the art of treatment Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Question No 1: Which statement regarding 1 st line treatment of early
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationOn behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A.
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan for patients with advanced highrisk Hodgkin s lymphoma A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler,
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationElderly Patients with Hodgkin s Lymphoma: FIL experience. Massimo Federico University of Modena and Reggio Emilia
Elderly Patients with Hodgkin s Lymphoma: FIL experience Massimo Federico University of Modena and Reggio Emilia RESULTS OF VbMp CHEMOTHERAPY REGIMEN IN ELDERLY PATIENTS WITH HODGKIN DISEASE: THE GISL
More informationTreatment of Early Stage Hodgkin Lymphoma. Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research
Treatment of Early Stage Hodgkin Lymphoma Massimo Federico University of Modena and Reggio Emilia Città di Lecce Hospital - GVM Care & Research Conflict of Interest Disclosure I hereby declare the following
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationHodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP. Volker Diehl for the German Hodgkin Study Group
Hodgkin Lymphoma Which Group of Patients benefits from the use of BEACOPP Volker Diehl for the German Hodgkin Study Group Moscow 25.October 2007 HD8 trial design CS IA, IB, IIA,B with risk factors Random
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationFirst Line Management of Classical Hodgkin Lymphoma
First Line Management of Classical Hodgkin Lymphoma George Follows Cambridge University Hospitals NHS Foundation Trust george.follows@addenbrookes.nhs.uk The controversial areas Early stage non-bulky /
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationRT in Hodgkin Lymphoma
RT in Hodgkin Lymphoma Lesser is better? Philip Poortmans, M.D. Ph.D. Radiation oncologist Tilburg, The Netherlands Radiation dose in Hodgkin Lymphoma Introduction Current evidence Guidelines 1.0 Early
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationHodgkin Lymphoma Review of characteristics and treatment of elderly patients
Hodgkin Lymphoma Review of characteristics and treatment of elderly patients Boris Böll M.D. German Hodgkin Study Group (GHSG) University Hospital Cologne OS of HL patients in all stages 1960-1967 Courtesy
More informationComparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
More informationResponse Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy
Response Adapted treatment of chl using BV in first line Massimo Federico University of Modena and Reggio Emilia Italy From the book of 18FDG-PET in BV treatment patients 1 In the beginning Seattle Genetics
More informationPrinted by Martina Huckova on 10/3/2011 3:04:43 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationWhatdidwelearnfromthe H10 trial? M. André
Whatdidwelearnfromthe H10 trial? M. André The H10 EORTC/LYSA/FIL randomized Intergroup trial on early FDG- PET scan guided treatment adaptation versus standard combined modality treatment in patients withsupradiaphragmaticstage
More informationHodgkin. The PET World. Sally Barrington
Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging
More informationGruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera S. Croce e Carle, Cuneo
Sponsor Principal Investigator Protocol Coordinators Coordinating Centre Writing committee CRO Gruppo Italiano Terapie Innovative nei Linfomi (G.I.T.I.L.) Dr. Andrea Gallamini S.C. Ematologia Az. Ospedaliera
More informationCure, Late Effects and Prevention in Hodgkin Lymphoma
Cure, Late Effects and Prevention in Hodgkin Lymphoma Michael Crump, MD, FRCPC Princess Margaret Hospital University of Toronto Toronto, Canada Objectives/Outline review progress in treatment of HL outline
More informationROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY
ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE
More informationLimited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment
HODGKIN LYMPHOMA: CLINICAL CHALLENGES Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment John Radford 1 1 Professor of Medical Oncology, Christie Hospital and The University of
More informationThe Present: Optimizing Therapy Too Much or Too Little?
CLINICAL ADVANCES IN HODGKIN LYMPHOMA The Present: Optimizing Therapy Too Much or Too Little? Nancy L. Bartlett 1 1 Siteman Cancer Center, Washington University, St. Louis, MO Despite the use of less toxic
More informationNIH Public Access Author Manuscript Expert Opin Pharmacother. Author manuscript; available in PMC 2011 December 1.
NIH Public Access Author Manuscript Published in final edited form as: Expert Opin Pharmacother. 2010 December ; 11(17): 2891 2906. doi:10.1517/14656566.2010.515979. Hodgkin s Lymphoma Therapy: Past, Present,
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationEarly interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS).
Early interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS). A Gallamini Hematology Department and BMT Unit, Santa Croce Hospital Cuneo - Italy S. Barrington
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationNews from EHA. Linfomi. Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma
News from EHA Linfomi Maurizio Martelli Dip. Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Outline HD advanced disease first line therapy : intensity of chemotherapy and PET guided
More informationHodgkin Lymphoma-Stage III and IV EVIDENCE TABLE
. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. 2. Lister TA, Crowther D, Sutcliffe SB, et al. Report
More informationPan-London Haemato-Oncology Clinical Guidelines. Lymphoid Malignancies Part 1: Hodgkin Lymphoma
Pan-London Haemato-Oncology Clinical Guidelines Lymphoid Malignancies Part 1: Hodgkin Lymphoma September 2018 CONTENTS Contents 1 Introduction... 3 2 Referral Pathways from Primary Care... 3 3 Investigation
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationFirst line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early versus Advanced Stage Disease Presented
[Editor s note: Dr. Even's video transcript has been edited to improve readability] you today about the management of Hodgkin lymphoma in 2016. Welcome to Managing Hodgkin Lymphoma. My name is Andy Evens,
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationLate relapse of Hodgkin s lymphoma is it different in clinical characteristics and outcome?
JBUON 2017; 22(2): 481-486 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Late relapse of Hodgkin s lymphoma is it different in clinical characteristics
More informationRole of modern radiation therapy in early stage Hodgkin s lymphoma: A young radiation oncologists perspective
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 246 250 Available online at www.sciencedirect.com jo u r n al hom epage: http://www.elsevier.com/locate/rpor Review Role of modern radiation
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationRisk, Cure and Complications in Advanced Hodgkin Disease
Risk, Cure and Complications in Advanced Hodgkin Disease Sandra J. Horning Stanford University, Stanford, CA Current therapy for Hodgkin disease is aimed at high cure rates and optimal survivorship. Although
More informationHodgkin Lymphom Aktuelle Strategien und Studien Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of Cologne
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Hodgkin Lymphom Aktuelle Strategien und Studien Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of Cologne Hodgkin
More informationGuidelines for the first line management of classical Hodgkin lymphoma
guideline Guidelines for the first line management of classical Hodgkin lymphoma George A. Follows, 1 Kirit M. Ardeshna, 2 Sally F. Barrington, 3 Dominic J. Culligan, 4 Peter J. Hoskin, 5 David Linch,
More informationTreatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching Hospital Experience
Original Article Treatment of Forty Adult Patients with Hodgkin Disease; Baghdad Teaching * Alaadin S. Naji* Ahmed A. AL - Saffar* Mazin A. Shubbar* Bassam F. Matti* Adil Siwan* Ammar F. Majeed* Ali M.Jawad*
More informationOne, the UK RAPID trial, including patients with early stage disease stage 1 and 2A nonbulky.
Martin Hutchings, MD, PhD Department of Hematology The Finsen Centre, National Hospital Copenhagen University Hospital Copenhagen, Denmark Welcome to Managing Hodgkin Lymphoma. My name is Martin Hutchings.
More informationAt initial diagnosis, patients with
Malignant Lymphomas Decision Making and Problem Solving Current treatment and immunotherapy of Hodgkin s lymphoma Beate Klimm Roland Schnell Volker Diehl Andreas Engert The treatment of Hodgkin s lymphoma
More informationHodgkin Lymphoma-Unfavorable Clinical Stage I and II EVIDENCE TABLE
. Kaplan HS. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res. 966;6(6):-4.. Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin's
More informationTHE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982)
EORTC Lymphoma Group THE EORTC-GELA TREATMENT STRATEGY IN CLINICAL STAGES I-II HL Results of the H9-F and H9-U trials (#20982) J. Thomas, C. Fermé, E.M. Noordijk, H. Eghbali and M. Henry-Amar 7th International
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationSerum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma
Original article Annals of Oncology 13: 1908 1914, 2002 DOI: 10.1093/annonc/mdf333 Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin s lymphoma
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationLa TEP dans le lymphome Impacts cliniques en Olivier Casasnovas Hématologie Clinique CHU Dijon
La TEP dans le lymphome Impacts cliniques en 2017 Olivier Casasnovas Hématologie Clinique CHU Dijon Incidence and Anatomic Regions Detected by FDG PET Relation to Histologic Types According to World Health
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationLymphocyte-Depleted Classical Hodgkin s Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
Published Ahead of Print on September 12, 211 as 1.12/JCO.211.36.473 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.211.36.473 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationDr. Andrea Gallamini - Hematology Department Azienda Ospedaliera S. Croce e Carle Cuneo Italy
High-dose sequential chemotherapy (HDS) followed by autologous stem cell transplantation (ASCT) in relapsed/refractory Hodgkin s lymphoma. Long term results. Dr. Andrea Gallamini - Hematology Department
More informationEnd-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin s lymphoma
original article Annals of Oncology 22: 910 915, 2011 doi:10.1093/annonc/mdq549 Published online 15 October 2010 original article End-of-treatment but not interim PET scan predicts outcome in nonbulky
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationHodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease
Hodgkin s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease Volker Diehl, Harald Stein, Michael Hummel, Raphael Zollinger, and Joseph M. Connors Hodgkin s lymphomas
More informationNon-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection. Arnold Freedman, M.D.
2017 Master Class for Oncologists Non-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection Arnold Freedman, M.D. 2018 Master Class Course Disclosure Disclosure
More informationWelcome & Introductions
Living with Hodgkin Lymphoma Welcome & Introductions Dr. Lamar s slides are available for download at www.lls.org/programs, under the program listing. 1 Living with Hodgkin Lymphoma Living with Hodgkin
More informationInterim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience
Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience MD. Caballero, Hospital Universitario, Salamanca, Spain. Chair of The GEL/TAMO Group Menton,9 april 2010 Disclosures for Dolores Caballero
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationHodgkin Lymphoma: Umberto Ricardi
Hodgkin Lymphoma: Radiation Volumes Umberto Ricardi Università di Torino The changing role of RT in the cure of HL From Maximal use as a single agent To Combination of chemotherapy and full dose-full volume
More informationXVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma
Hematological Oncology Hematol Oncol 2015; 33: 90 95 Published online in Wiley Online Library (wileyonlinelibrary.com).2226 Supplement Article XVIII. Management of nodular lymphocyte predominant Hodgkin
More informationClinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma
Original Article Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma Authors: Shinichi Makita 1, 4, Dai Maruyama 1, Akiko Miyagi Maeshima 2, Hirokazu Taniguchi 2, Ken-ichi Miyamoto
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationREVIEW ARTICLES ABSTRACT. EJD and RBS contributed equally to this manuscript.
REVIEW ARTICLES A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin
More informationPediatric Lymphoma Update from the Children s Oncology Group
Pediatric Lymphoma Update from the Children s Oncology Group Stephan D. Voss, MD, PhD Department of Radiology Boston Children s Hospital Harvard Medical School Staging Assessment Disclosures None Acknowledgements:
More informationWelcome and Introductions
Update on Hodgkin Lymphoma Matthew J Matasar, MD, MS Physician, Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York, NY April 1, 2016
More informationHEMATOLOGY Board Review Manual
Volume 7, Part 4 November 2012 HEMATOLOGY Board Review Manual Advanced-Stage and Relapsed/ Refractory Hodgkin Lymphoma HEMATOLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationEvolving Approaches to Primary Treatment of Hodgkin Lymphoma
Evolving Approaches to Primary Treatment of Hodgkin Lymphoma Joseph M. Connors Two challenges confront the clinician treating Hodgkin lymphoma today: achieving a high level of effectiveness while minimizing
More informationA Practical Guide to PET adapted Therapy for Hodgkin Lymphoma
Hello. My name is Peter Johnson. I am a Professor of Medical Oncology in Southampton in the UK and I am speaking today on behalf of Managing Hodgkin Lymphoma, and particularly, I am going to talk about
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationPrinciples of Chemotherapy in Hodgkin Lymphoma
Principles of Chemotherapy in Hodgkin Lymphoma 9 Patrice Carde and Peter Johnson Contents 9.1 Historical Introduction... 141 9.2 Chemotherapy Applied to Advanced Stage HL: Theories and Practice... 142
More informationASTRO Refresher Course Lymphoma. Chris Kelsey, M.D. Duke University Medical Center
ASTRO Refresher Course 2015 Lymphoma Chris Kelsey, M.D. Duke University Medical Center Disclosure Varian Medical Systems Research funding for lung cancer trial Learning Objectives Awareness of Deauville
More informationHodgkin Lymphoma: Robert Chen, MD 2/05/15. City of Hope National Medical Center
Hodgkin Lymphoma: Robert Chen, MD 2/05/15 City of Hope National Medical Center Disclosures I receive grant/research support from Seattle Genetics and Millennium. I am also a consultant for Seattle Genetics,
More informationLow acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkins disease
Ann Hematol (2004) 83:176 182 DOI 10.1007/s00277-003-0727-9 ORIGINAL ARTICLE O. Brosteanu D. Hasenclever M. Loeffler V. Diehl German Hodgkin s Lymphoma Study Group Low acute hematological toxicity during
More informationHodgkin Lymphoma. Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois
Hodgkin Lymphoma Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois Hodgkin Lymphoma Successes and Challenges The success 80 % of patients achieve
More informationHodgkin Lymphoma in Older Patients
Hodgkin Lymphoma in Older Patients Andrew M. Evens, DO, MSc March 26 th, 2015 Professor of Medicine Chief, Division of Hematology/Oncology Director, Tufts Cancer Center Tufts Medical Center Elderly Hodgkin
More informationPost-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
More informationEarly and intermediate stage Hodgkin's lymphoma - report from the Swedish National Care Programme.
Early and intermediate stage Hodgkin's lymphoma - report from the Swedish National Care Programme. Molin, Daniel; Enblad, Gunilla; Gustavsson, Anita; Ekman, Tor; Erlanson, Martin; Haapaniemi, Eva; Glimelius,
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationResponse-adapted frontline therapy for Hodgkin lymphoma: are we there yet?
HODGKIN LYMPHOMA: TREATMENT TODAY AND THE CHALLENGE FOR TOMORROW Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? Peter W. M. Johnson Cancer Research UK Centre, University of
More informationPoster Discussion : Hodgkin Lymphoma
3 rd INTERNATIONAL WORKSHOP ON INTERIM-PET IN LYMPHOMA Poster Discussion : Hodgkin Lymphoma A. Gallamini T. Vander Borght Hodgkin Lymphoma 1. Technical abstracts Diagnostic criteria (scale, children, when?)
More information